$TMDX, a company focused on transplant solutions, has seen its stock price decline by 60% following a weak Q3 performance. However, recent indicators suggest a potential recovery. Analysts note that the company's flight utilization rates have significantly increased, with December recording the highest number of flights ever. Despite a 26% short interest in the stock, some investors believe that the market misinterpreted the Q3 results as temporary setbacks. There are expectations for new guidance from the company, particularly ahead of the upcoming JPM conference. The headwinds affecting US transplant numbers, especially for liver transplants—which account for over 70% of $TMDX's revenue—are believed to have subsided in Q4, further supporting the outlook for recovery.